Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris
Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris
Shots:
- Glenmark to receive upfront, milestones and royalties on sales from Yuhan. Yuhan to get exclusive commercialization rights for Glenmark’s Ryaltris in South Korea
- Yuhan will be responsible for its regulatory approval and Glenmark to take care of manufacturing and supply of Ryaltris in South Korea
- Ryaltrisis a FD combination of anti-histamine and steroid i.e olopatadine hydrochloride (665 mcg) & mometasone furoate (25 mcg) indicated to treat symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age. In May 2018 Glenmark filled Ryaltris’ NDA to the US FDA and is currently reviewed
Click here to read full press release/ article | Ref: Glenmark | Image: DNA India